Published in final edited form as:

Tetrahedron Lett. 2012 August 8; 53(32): 4202–4205. doi:10.1016/j.tetlet.2012.05.156.

Secondary metabolites produced by fungi derived from a microbial mat encountered in an iron-rich natural spring

Alexandra L. Gereaa,[†], Katie M. Branscum^{b,†}, Jarrod B. King^a, Jianlan You^a, Douglas R. Powell^b, Andrew N. Miller^c, John R. Spear^d, and Robert H. Cichewicz^{a,*}

^aNatural Products Discovery Group, Department of Chemistry and Biochemistry, Stephenson Life Sciences Research Center 101 Stephenson Parkway, Room 1000, University of Oklahoma, Norman, Oklahoma, 73019-5251, USA

^bDepartment of Chemistry and Biochemistry, Stephenson Life Sciences Research Center 101 Stephenson Parkway, Room 1000, University of Oklahoma, Norman, Oklahoma, 73019-5251, USA

^cUniversity of Illinois, Illinois Natural History Survey, 1816 South Oak Street, Champaign, IL 61820-6970, USA

^dDepartment of Civil and Environmental Engineering, Colorado School of Mines, Golden, CO 80401-1887, USA

Abstract

A collection of fungal isolates was obtained from a complex microbial mat, which occupied an iron-rich freshwater spring that feeds into Clear Creek, Golden, Colorado, USA. Two of the fungal isolates, a Glomeromycete (possible *Entrophospora* sp.) and a Dothideomycete (possible *Phaeosphaeria* sp.), were investigated for bioactive secondary metabolites. In total, six new compounds consisting of clearanols A–E (**5**, **6**, **10–12**) and disulochrin (**7**) were purified and their structures were determined. Disulochrin exhibited modest antibacterial activity against methicillin-resistant *Staphylococcus aureus*, whereas clearanol C showed weak inhibitory activity against *Candida albicans* biofilm formation.

Keywords

Biofilm; Fungi; Microbial mat; Secondary metabolites

Polymicrobial biofilms and mats are found in many natural settings at the interfaces between liquids and solid substrates.^{1–5} Recognizing that these types of environments may provide ideal conditions for promoting interspecies metabolic exchange within and between all three domains of life,⁶ we have sampled a limited number of naturally-occurring microbial mats

© 2012 Elsevier Ltd. All rights reserved.

*Corresponding author. Tel.: +1 405 325 6969; fax: +1 405 325 6111. rhcichewicz@ou.edu (R. Cichewicz).

[†]To be considered joint first authors.

Supplementary data

Supplementary data (X-ray diffraction experiment for **5**) associated with this article can be found, in the online version, at WEB LINK TO BE INSERTED.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

for new secondary-metabolite-producing fungi. During the summer of 2010, one of the many springs that feed into Clear Creek near Golden, CO, USA (39°45'15.0" North, 105°13'39.9" West, elevation 1729 meters) was host to a luxuriant microbial mat that appeared bright green due to an abundance of photosynthetic algae and cyanobacteria. However, by early autumn, the mat had developed an intense orange hue as iron-oxidizing *Gallionella*⁷ became dominant in the iron-rich waters of the spring (4–7 mg/L iron in the spring versus 0.01–1.4 mg/L within the creek). Closer inspection of the mat revealed that a biodiverse mixture of other bacteria, as well as Archaea and Eukarya were present and a sample was collected for the purpose of procuring fungal isolates. In this report, we describe the structure assignments and bioassay screening results for metabolites purified from two fungal isolates obtained from the Clear Creek microbial mat. The results from this investigation provide compelling evidence that naturally-occurring microbial communities offer unique opportunities for obtaining fungi that generate new bioactive compounds.

The Clear Creek mat sample was mechanically disrupted and aliquots of the microbial suspension were placed on Petri plates containing either Czapek or soil-extract agar with chloramphenicol. After two weeks of incubation at room temperature, fungal colonies were transferred to Czapek agar plates. This afforded 32 fungal isolates (20 from Czapek agar and 12 from soil-extract agar) that appeared distinct based on gross morphological features. Small-scale shake-flask cultures of the isolates were prepared and extracted with ethyl acetate. Upon removal of the solvent, the remaining organic residues were tested in our assay panel for antibacterial, antifungal, cancer cell cytotoxicity, and inhibition of *Candida* biofilm formation. The fungal isolates were also subjected to sequencing of their nuclear ribosomal internal transcribed spacer (ITS) regions. BLAST searches performed on the sequence data revealed that the majority of the fungi were taxonomically affiliated with isolates that were scantily studied or had not been subjected to prior analyses of their secondary metabolites (based on queries of the SciFinder[®] and Dictionary of Natural Products[®] databases). Two of the relatively uncommon isolates, a Glomeromycete (possible *Entrophospora* sp., GenBank accession no. JQ958304) and a Dothideomycete (possible *Phaeosphaeria* sp., GenBank accession no. JQ958305), were chosen for scale-up chemical investigations.

An examination of different media formulations led to the observation that the Glomeromycete isolate grew particularly well under static conditions on a medium composed of Cheerios[®] breakfast cereal supplemented with a 3% sucrose solution. The fungal cultures were extracted with MeOH to give a dark reddish-rust colored extract that was subjected to a combination of silica gel chromatography and C18 HPLC. This provided several known compounds in substantial quantities including sulochrin (**1**) (218 mg), hydroxysulochrin (**2**) (12 mg), questinol (**3**) (57 mg), questin (**4**) (11 mg), and three new compounds (**5–7**) (Fig. 1).

Compound **5** (30 mg)⁸ (Fig. 1) was assigned the molecular formula C₁₁H₁₄O₅ based on HRESIMS (m/z 227.0909 [M+H]⁺, calcd for C₁₁H₁₅O₅ 227.0914), which corresponded to five degrees of unsaturation. Inspection of the ¹H NMR, ¹³C NMR, and ¹H-¹³C HSQC data provided evidence for five quaternary carbons, two methines, two methylenes, and two methyl groups. The ¹H-¹³C HMBC correlations (Fig. 2) were instrumental in piecing together compound **5** as the only reasonable planar structure for this metabolite. The structure of **5** was later confirmed by single crystal X-ray diffraction,⁹ which also supported an 11*R* absolute configuration for the metabolite (Fig. 3) (determined by Hooft parameter, refer to the supplementary information for additional details). Examination of the SciFinder database revealed that although the planar version of this compound had been previously assigned a CAS registry number (1235630-76-8), no references were available concerning

its spectroscopic properties or synthetic/biosynthetic origins. We have given compound **5** the trivial name clearanol A.

Compound **6** (0.7 mg)¹⁰ (Fig. 1) exhibited ¹H and ¹³C NMR data that were similar to those acquired for **5**; however, the HRESIMS data revealed that this metabolite possessed one additional degree of unsaturation (m/z 247.0573 [M+Na]⁺, calcd for C₁₁H₁₂O₅Na 247.0582). The downfield shift of C-5 from δ 55.9 in **5** to δ 87.7 in **6** indicated that the C-7 hydroxyl group formed a new ether linkage to C-5 resulting in a dioxygenated carbon atom. This was readily confirmed with the appearance of two new ³J_{H-C} HMBC correlations extending from H-5 to C-7 (Fig. 2). Compound **6** has been given the trivial name clearanol B. The metabolite degraded upon storage and consequently its relative/absolute configuration was not investigated.

A molecular formula of C₃₅H₃₂O₁₄ was established for compound **7** (7 mg)¹¹ (Fig. 1) based on HRESIMS (m/z 699.1685 [M+Na]⁺, calcd for C₃₅H₃₂O₁₄Na 699.1689), which accounted for 20 degrees of unsaturation. Surprisingly, the ¹³C NMR data for **7** exhibited only 18 resonances and 17 of the resonances had nearly identical chemical shifts to co-occurring metabolite **1** (C₁₇H₁₆O₇). Therefore, we suspected that **7** was a symmetric dimeric compound. After accounting for 17 carbon resonances attributable to **1**, a single new methylene signal remained (C-18) that we deduced would serve as a bridge between two sulochrin moieties. ¹H-¹³C HMBC correlations were observed from the new H-18 methylene protons to C-14/14', C-15/15', and C-16/16', which confirmed that the methylene served as a link between C-15 and C-15'. Compound **7** is structurally similar to acremonidin D, which is the dimerized product of the demethoxy sulochrin analog, acremonidin E¹². Metabolite **7** has been assigned the trivial name disulochrin.

The Dothideomycete isolate was grown on Cheerios® supplemented with a 3% sucrose solution and the cultures were extracted with ethyl acetate to afford a brown gummy extract. The extract was subjected to Sephadex LH-20 chromatography and C18 HPLC. This provided five metabolites, two of which were identified by dereplication. Compound **8** (5 mg) was determined to be (*R*)-4,8-dihydroxy-6-methoxy-4,5-dimethyl-3-methyleneisochroman-1-one^{13,14} and **9** (20 mg) was identified as (*R*)-7-hydroxy-3-((*S*)-1-hydroxyethyl)-5-methoxy-3,4-dimethylisobenzofuran-1(3*H*)-one.¹⁴ The absolute configurations of the metabolites were confirmed by comparisons of their circular dichroism data to those reported by Tayone et al.¹⁴

Compound **10** (3 mg)¹⁵ was assigned the molecular formula C₁₃H₁₄O₄ by HRESIMS (m/z 233.0815 [M-H]⁻, calcd for C₁₃H₁₃O₄, 233.0814), which accounted for seven degrees of unsaturation. The considerable similarities of the ¹H and ¹³C NMR data for **10** and **8** suggested that these metabolites were structurally related. However, a notable difference between the two metabolites concerned C-8 which was shifted upfield from δ 72.1 in **8** to δ 36.0 in **10**. In addition, the ¹H-¹³C HSQC experiment demonstrated that the C-8 quaternary carbon in **8** was a methine in **10**. These data indicated that **10** was the C-8 de-hydroxy analog of metabolite **8**. Subsequent analysis of all the ¹H-¹³C HMBC correlation data led to the assignment of the planar structure of **10** (Fig. 2). We have given compound **10** the name clearanol C.

Compounds **11**¹⁶ and **12**¹⁷ were obtained as a 1:1 mixture (39 mg) of structurally-related metabolites that resisted chromatographic separation by C18 HPLC with aqueous MeOH and acetonitrile. However, examination of the mixture by ¹H and ¹³C NMR led us to conclude that the structures of both metabolites could be deduced in their combined form. HRESIMS performed on the mixture yielded a single peak at m/z 291.0839 [M+Na]⁺, which represented a molecular formula of C₁₃H₁₆O₆, (calcd for C₁₃H₁₆O₆Na, 291.0845) for both

compounds. In view of the identical molecular formulae and very similar NMR data for these metabolites, it was deduced that **11** and **12** represented a diastereomeric mixture. We also noted that **11** and **12** showed considerable similarity to **9** with the following exceptions: the highfield C-10 methyl doublet protons found in **9** (δ 0.86, J = 6.3 Hz) were missing and instead were replaced by downfield diastereotopic methylene double doublets in **11** (δ 3.83, J = 11.3, 3.5 Hz and δ 3.53, J = 11.3, 8.2 Hz) and **12** (δ 3.34, J = 11.3, 8.6 Hz and δ 3.14, J = 11.3, 2.7 Hz). This suggested that the additional oxygen atoms in the molecular formulae of **11** and **12** were accounted for by new C-10 hydroxyl groups. ^1H - ^{13}C HMBC correlations from the C-10 protons of both compounds to their respective C-8 and C-9 carbon atoms (Fig. 2) confirmed these assignments. Further analysis of the ^1H - ^{13}C HMBC correlation data for both metabolites provided verification of the planar structures of **11** and **12** and we have given these compounds the trivial names clearanols D and E, respectively.

All compounds were tested in bioassays that were performed as previously described.^{18,19} Compound **7** exhibited modest activity against methicillin-resistant *Staphylococcus aureus* (ATCC 700787) by completely inhibiting its growth at a concentration of 100 $\mu\text{g/mL}$; however, growth was not restricted at 10 $\mu\text{g/mL}$. None of the other compounds inhibited the growth of *S. aureus* or *Klebsiella pneumoniae* (ATCC 51503). Metabolite **10** demonstrated modest growth inhibition effects against polyene-resistant *Candida albicans* (ATCC 38245) and *Aspergillus fumigatus* (FGSC A1100) by reducing growth 61% and 62%, respectively, at 100 $\mu\text{g/mL}$. None of the other metabolites inhibited the growth of fungi or pancreatic cancer cells (MIA-PaCa-2). Compounds **8** and **10** inhibited *C. albicans* (DAY185) biofilm formation with MIC values of 86 ± 3 and 101 ± 3 μM , respectively. None of the other metabolites demonstrated activity in the biofilm assay. Based on these studies, we surmise that microbial mat communities offer intriguing potential for encountering unusual fungal taxa with the capacity to generate new bioactive natural products.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial support from the National Institutes of Health (1R01GM092219 and 1R01AI085161) is greatly appreciated. The X-ray diffractometer was purchased through a grant from the National Science Foundation (CHE-0130835).

References and notes

- Robertson CE, Spear JR, Harris JK, Pace NR. Appl Environ Microbiol. 2009; 75:1801–1810. [PubMed: 19114531]
- Feazel LM, Spear JR, Berger AB, Harris JK, Frank DN, Ley RE, Pace NR. Appl Environ Microbiol. 2008; 74:329–332. [PubMed: 17993566]
- Hall-Stoodley L, Costerton JW, Stoodley P. Nat Rev Microbiol. 2004; 2:95–108. [PubMed: 15040259]
- Seckbach, J.; Oren, A. Microbial Mats: Modern and Ancient Microorganisms in Stratified Systems. Springer; New York: 2010.
- Ley RE, Harris JK, Wilcox J, Spear JR, Miller SR, Bebout BM, Maresca JA, Bryant DA, Sogin ML, Pace NR. Appl Environ Microbiol. 2006; 72:3685–3695. [PubMed: 16672518]
- Phelan VV, Liu WT, Pogliano K, Dorrestein PC. Nat Chem Biol. 2012; 8:26–35. [PubMed: 22173357]
- Emerson D, Fleming EJ, McBeth JM. Ann Rev Microbiol. 2010; 64:561–583. [PubMed: 20565252]
- Clearanol A* (**5**): colorless crystals from MeOH; mp 138–140 °C; $[\alpha]_D^{24}$ -88 (c 0.4, MeOH); UV (MeOH) λ_{max} nm (log ϵ) 210 (4.35), 290 (3.91); IR (NaCl) ν_{max} 3387, 2972, 2346, 1700, 1629,

1560, 1452, 1406, 1246, 1017 cm^{-1} ; ^1H NMR (500 MHz, methanol- d_4) δ 5.75 (1H, d, $J=1.5$ Hz, H-9a), 5.67 (1H, s, H-3), 5.63 (1H, d, $J=1.5$ Hz, H-9b), 4.64 (1H, q, $J=6.6$ Hz, H-7), 4.44 (1H, d, $J=11.7$ Hz, H-5a), 4.33 (1H, d, $J=11.7$ Hz, H-5b), 3.94 (3H, s, H-11), 1.30 (3H, d, $J=6.6$ Hz, H-10); ^{13}C NMR (125 MHz, methanol- d_4) δ 172.9 (C-4), 166.1 (C-2), 163.1 (C-8a), 146.0 (C-8), 119.8 (C-9), 114.4 (C-4a), 89.5 (C-3), 68.3 (C-7), 57.5 (C-11), 55.9 (C-5), 22.6 (C-10); HRESIMS m/z 227.0909 $[\text{M}+\text{H}]^+$ (calcd for $\text{C}_{11}\text{H}_{15}\text{O}_5$, 227.0914).

9. Cambridge Crystallographic Data Centre no. CCDC 876681; experimental parameters are provided in the online supplementary data accompanying this report.
10. *Clearanol B* (**6**): amorphous powder; UV (MeOH) λ_{max} nm (log ϵ) 206 (4.29), 298 (3.84); IR (NaCl) ν_{max} 3345, 2922, 2853, 2347, 1707, 1609, 1564, 1461, 1408, 1260, 1055 cm^{-1} ; ^1H NMR (400 MHz, methanol- d_4) δ 5.97 (1H, d, $J=1.6$ Hz, H-9a), 5.83 (1H, s, H-5), 5.70 (1H, s, H-3), 5.48 (1H, d, $J=1.6$ Hz, H-9b), 4.92 (1H, m, $J=6.3$ Hz, H-7), 3.92 (3H, s, H-11), 1.47 (3H, d, $J=6.3$ Hz, H-10); ^{13}C NMR (100 MHz, methanol- d_4) δ 170.7 (C-4), 165.6 (C-2), 153.9 (C-8a), 138.7 (C-8), 114.5 (C-9), 111.4 (C-4a), 90.5 (C-3), 87.7 (C-5), 65.4 (C-7), 57.6 (C-11), 18.4 (C-10); HRESIMS m/z 247.0573 $[\text{M}+\text{Na}]^+$ (calcd for $\text{C}_{11}\text{H}_{12}\text{O}_5\text{Na}$ 247.0582).
11. *Disulochrin* (**7**): yellow amorphous powder; UV (MeOH) λ_{max} nm (log ϵ) 210 (4.64), 288 (3.90); IR (NaCl) ν_{max} 3301, 2953, 2352, 1710, 1609, 1589, 1441, 1344, 1145, 1064, 1004 cm^{-1} ; ^1H NMR (400 MHz, methanol- d_4) δ 6.95 (1H, d, $J=2.0$ Hz, H-5), 6.65 (1H, d, $J=2.0$ Hz, H-3), 6.00 (1H, s, H-13), 3.98 (1H, s, H-18), 3.70 (3H, s, H-7), 3.62 (3H, s, H-9), 2.17 (3H, s, H-17); ^{13}C NMR (75 MHz, methanol- d_4) δ 202.4 (C-10,10'), 168.2 (C-8,8'), 162.7 (C-12,12'), 159.8 (C-4,4'), 159.5 (C-16,16'), 158.8 (C-2,2'), 149.3 (C-14,14'), 130.1 (C-6,6'), 128.4 (C-1,1'), 119.0 (C-15,15'), 110.8 (C-11,11'), 109.4 (C-13,13'), 109.0 (C-5,5'), 104.4 (C-3,3'), 56.7 (C-7,7'), 52.7 (C-9,9'), 22.0 (C-18), 21.1 (C-17,17'); HRESIMS m/z 699.1685 $[\text{M}+\text{Na}]^+$ (calcd for $\text{C}_{35}\text{H}_{32}\text{O}_{14}\text{Na}$ 699.1689).
12. He H, Bigelis R, Solum EH, Greenstein M, Carter GT. J Antibiot. 2003; 56:923–930. [PubMed: 14763558]
13. Chinworrungsee M, Kittakoo P, Isaka M, Chanphen R, Tanticharoen M, Thebtaranonth Y. J Chem Soc, Perkin Trans. 2002; 1:2473–2476.
14. Tayone WC, Honma M, Kanamaru S, Noguchi S, Tanaka K, Nehira T, Hashimoto M. J Nat Prod. 2011; 74:425–429. [PubMed: 21265556]
15. *Clearanol C* (**10**): amorphous solid, $[\alpha]_{\text{D}}^{22} +39$ (c 0.06, MeOH); UV (MeOH) λ_{max} nm (log ϵ) 220 (3.83), 270 (3.47), 312 (3.20); IR (NaCl) ν_{max} 3623, 2949, 2851, 1651, 1018 cm^{-1} ; ^1H NMR (400 MHz, methanol- d_4) δ 6.46 (1H, s, H-4), 4.74 (1H, s, H-10a), 4.68 (1H, s, H-10b), 3.99 (1H, q, $J=7.0$ Hz, H-8), 3.88 (3H, s, H-13), 2.09 (3H, s, H-12), 1.34 (3H, d, $J=7.0$ Hz, H-11); ^{13}C NMR (100 MHz, methanol- d_4) δ 168.4 (C-5), 166.6 (C-1), 164.4 (C-3), 159.1 (C-9), 143.8 (C-7), 115.5 (C-6), 99.5 (C-2), 98.5 (C-4), 96.2 (C-10), 56.6 (C-13), 36.0 (C-8), 22.7 (C-11), 10.2 (C-12); HRESIMS m/z 233.0815 $[\text{M}-\text{H}]^-$ (calcd for $\text{C}_{13}\text{H}_{13}\text{O}_4$, 233.0814).
16. *Clearanol D* (**11**): amorphous solid (1:1 mixture with **12**); UV (MeOH) λ_{max} nm (log ϵ) 218 (4.22), 260 (3.87), 300 (3.59); IR (NaCl) ν_{max} 3596, 3089, 1737, 1651, 1472, 1373, 1319, 1247, 1220, 1153, 1067 cm^{-1} ; ^1H NMR (400 MHz, methanol- d_4) δ 6.47 (1H, s, H-4), 4.13 (1H, dd, $J=3.7$ and 8.0 Hz, H-9), 3.87 (3H, s, H-13), 3.83 (1H, dd, $J=3.5$ and 11.3 Hz, H-10a), 3.53 (1H, dd, $J=8.2$ and 11.3 Hz, H-10b), 2.18 (3H, s, H-12), 1.67 (3H, s, H-11); ^{13}C NMR (100 MHz, methanol- d_4) δ 171.9 (C-1), 166.4 (C-5), 157.8 (C-3), 153.1 (C-7), 113.4 (C-6), 105.4 (C-2), 99.5 (C-4), 90.6 (C-8), 75.7 (C-9), 63.9 (C-10), 56.9 (C-13), 22.08 (C-11), 11.4 (C-12); HRESIMS m/z 291.0839 $[\text{M}+\text{Na}]^+$ (calcd for $\text{C}_{13}\text{H}_{16}\text{O}_6\text{Na}$, 291.0845).
17. *Clearanol E* (**12**): amorphous solid (1:1 mixture with **11**); UV (MeOH) λ_{max} nm (log ϵ) 218 (4.22), 260 (3.87), 300 (3.59); IR (NaCl) ν_{max} 3596, 3089, 1737, 1651, 1472, 1373, 1319, 1247, 1220, 1153, 1067 cm^{-1} ; ^1H NMR (400 MHz, methanol- d_4) δ 6.49 (1H, s, H-4), 4.11 (1H, dd, $J=2.7$ and 8.2 Hz, H-9), 3.88 (3H, s, H-13), 3.34 (1H, dd, $J=8.6$ and 11.3 Hz, H-10a), 3.14 (1H, dd, $J=2.7$ and 11.3 Hz, H-10b), 2.15 (3H, s, H-12), 1.73 (3H, s, H-11); ^{13}C NMR (100 MHz, methanol- d_4) δ 171.5 (C-1), 166.6 (C-5), 158.3 (C-3), 152.4 (C-7), 113.3 (C-6), 104.6 (C-2), 99.9 (C-4), 90.4 (C-8), 76.2 (C-9), 63.3 (C-10), 56.9 (C-13), 22.11 (C-11), 11.7 (C-12); HRESIMS m/z 291.0839 $[\text{M}+\text{Na}]^+$ (calcd for $\text{C}_{13}\text{H}_{16}\text{O}_6\text{Na}$, 291.0845).
18. Wang X, You J, King JB, Powell DR, Cichewicz RH. J Nat Prod. 2012; 75:707–715. [PubMed: 22400916]

19. Henrikson JC, Ellis TK, King JB, Cichewicz RH. J Nat Prod. 2011; 74:1959–1964. [PubMed: 21854017]

Figure 1.
Structures of clearanols A–E (5, 6, 10–12) and disulochrin (7).

Figure 2.
Key $^2-3J_{\text{H-C}}$ ^1H - ^{13}C HMBC correlations used to determine the structures of **5**, **6**, **10**–**12**.

Figure 3.
Structure of **5** determined by single crystal X-ray diffraction experiment.